Acute Myelogenous Leukemia Clinical Trial
Official title:
Phase I Trial of CEDIRANIB (AZD2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors
Background:
- AZD2171 is an experimental drug that may slow the growth of cancers by blocking
angiogenesis (formation of new blood vessels).
- Cancer growth is dependent on angiogenesis for nutrition.
- Inhibiting angiogenesis is a new approach to cancer therapy.
Objectives:
- To determine the side effects of AZD2171 in children and adolescents with cancer.
- To determine the highest dose of AZD2171 that can safely be given to children and
adolescents with cancer.
- To study how the body handles AZD2171.
- To determine the effects of AZD2171 on various factors related to angiogenesis.
- To determine if AZD2171 can inhibit cancer growth in children and adolescents.
Eligibility:
-Children and adolescents 2-18 years of age with treatment-resistant solid tumor cancers or
acute myelogenous leukemia.
Design:
- About 40 patients may be included in the study.
- AZD2171 is given by mouth in treatment cycles of once a day for 28 days. Treatment may
continue unless the cancer worsens or unacceptable side effects develop.
- Patients have periodic physical examinations, blood and urine tests and imaging tests
(CT, X-rays, MRI) to evaluate disease throughout the course of treatment. Additional
blood tests are done to study how the body handles AZD2171, to look for proteins that
stimulate angiogenesis, to determine if certain blood vessel cells are affected by
AZD2171, and for other research purposes.
- Biopsy tissue (when available) is examined for the receptor for new blood vessel
formation.
Background:
- Cediranib is a potent orally bioavailable inhibitor of VEGFR1, VEGFR2, VEGFR3 tyrosine
kinase activity, but also inhibits c-kit and PDGFR-Beta in vitro.
- Phase I trials of Cediranib are ongoing in adults and the drug is well tolerated at
doses up to 45 mg/d. The toxicity profile includes hypertension, hypoglycemia, elevated
LFTs, fatigue, dysphonia, diarrhea, nausea and vomiting.
Objectives:
- To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of orally
administered Cediranib on a daily for 28 consecutive days schedule in children and
adolescents with refractory childhood solid tumors.
- To define the toxicity spectrum of oral Cediranib in children and adolescents.
- To assess the pharmacokinetics and pharmacodynamics of oral Cediranib in children and
adolescents.
- Assess growth plate volume in the right knee using non-contrast MRI scans prior to and
during administration of cediranib.
Eligibility:
-Children and adolescents (greater than 2 yrs and less than 19 years of age) with
histologically confirmed relapsed or refractory extracranial solid tumors that are measurable
or evaluable.
Design:
- Cediranib will be administered orally, daily. Treatment cycles are 28 days with no break
in treatment between cycles. The starting dose level is 12 mg/m(2)/d with escalations to
17, 25, 35, and 50 mg/ m(2)/d, due to dose limiting toxicity in the initial 2 subjects
enrolled at 12 mg/m(2)/d the protocol was amended to restart dose escalation at 8
mg/m(2)/d.
- Detailed pharmacokinetic and pharmacodynamic studies will be performed during the first
28 day treatment cycle.
- The trial follows a standard phase I design with 3 to 6 patients per dose level and
standard definitions of MTD and DLT. Up to 28 patients will be entered on this trial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01200355 -
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01681537 -
Lenalidomide Plus Chemotherapy for AML
|
Phase 1 | |
Completed |
NCT01385423 -
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT01193400 -
Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years
|
Phase 2 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00981240 -
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
|
Phase 1 | |
Completed |
NCT00995332 -
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
|
Phase 1/Phase 2 | |
Completed |
NCT00726934 -
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
|
N/A | |
Completed |
NCT00378534 -
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
|
Phase 2 | |
Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT00789256 -
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
|
N/A | |
Completed |
NCT00098033 -
Investigation of Clofarabine in Acute Leukemias
|
Phase 2 | |
Completed |
NCT01020539 -
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT04709458 -
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
|
Phase 1 | |
Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
Terminated |
NCT02203773 -
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
|
Phase 1 |